As Chief Medical Officer of Arrowhead Pharmaceuticals, Dr. San Martin is responsible for guiding the Company’s research and development teams to help advance its growing pipeline of RNAi therapeutics leveraging the TRiM™ platform to target liver, lung, tumor, muscle and additional extra-hepatic tissues. Earlier in his career, Dr. San Martin served as Senior Vice President and Head of Global Clinical Development at Ultragenyx where he led the development of burosumab. Dr. San Martin also served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals where he was responsible for managing the medical, regulatory and clinical operations group focused on early clinical programs. He also spent time at Amgen and Eli Lilly where he led numerous development and medical affairs activities.